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Abstract
Background Cystinosis is characterized by intralysosomal
cystine accumulation, causing end stage renal disease
around 10 years of age if not treated with cysteamine.
Cystine accumulation in blood vessels might increase
atheroma formation or arterial stiffness and therefore
increase the risk for cardiovascular disease (CVD). This
study aimed to investigate the risk for CVD by non-
invasive measures of atherosclerosis (NIMA) and to
evaluate the effect of cysteamine treatment.
Patients and methods Thirteen Dutch adult cystinosis
patients were included. White blood cell (WBC) cystine
levels, glomerular filtration rate (GFR) and concommitant
medications were obtained from medical records. NIMA
included carotid intima-media thickness (cIMT, n=13),
pulse wave velocity (PWV, n=8) and pulse wave analysis
(PWA, n=6).
Results GFR ranged between 4-95 mL/min/1.73 m². All but
one patient were treated with cysteamine, mean WBC
cystine values ranged between 0.34-1.64 nmol cystine/mg
protein, 8 patients had mean WBC cystine levels <1 nmol
cystine/mg protein. When compared to healthy subjects,
cIMT and PWV levels were above normal values in 1
patient for each measure. PWA measurements showed high
augmentation index in three patients who did not receive
lipid-lowering medication. When corrected for renal func-
tion, cIMT and PWV levels were within the normal range.
Conclusion Young adult cystinosis patients treated with
cysteamine have no additional risk for CVD when
compared to patients with chronic kidney disease of other
causes.
Abbreviations
CVD Cardiovascular disease
CKD Chronic kidney disease
NIMA Non-invasive measures of atherosclerosis
cIMT Carotid intima-media thickness
PWV Pulse wave velocity
PWA Pulse wave analysis
AI Augmentation index
SEVR Sub-endocardial viability ratio
Introduction
Cystinosis is a metabolic disorder caused by mutations in
the CTNS gene, encoding the lysosomal cystine carrier
cystinosin. This results in intralysosomal accumulation of
the amino acid cystine (Town et al. 1998). The disease is
inherited in an autosomal recessive trait and has an
incidence of one case in every 100,000 to 200,000 live
births. Most children present during the first year of life
with generalized proximal tubular dysfunction called renal
Fanconi syndrome. If left untreated, the disease progresses
towards end-stage renal disease around the age of 10 years.
Besides renal involvement, the eyes, endocrine organs,
muscles and central nervous system are also affected.
Cystinosis is treated by administration of the cystine-
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gression of renal failure and protects extra-renal organs
(Gahl et al. 2002).
Prior to renal transplantation and cysteamine treatment,
the lifespan for children with cystinosis was approximately
10 years. Now cystinosis patients have survived through
their fifth decade, but the unremitting accumulation of
cystine has created significant extra-renal morbidity and
mortality. Ueda et al. found increased coronary and
vascular calcifications in cystinosis patients and hypothe-
sized that the accumulation of intracellular cystine itself
may be a risk factor for vascular calcifications. They
advised to screen older patients with cystinosis for this
complication (Ueda et al. 2006). We hypothesize that
cystine accumulation in blood vessels might increase
atheroma formation or arterial stiffness and therefore
increase the risk for cardiovascular disease CVD. Further-
more, it has been reported that patients with cystinosis
might be prone to hypercholesterolemia (Nesterova and
Gahl 2008, Murphy and Papathakis 1993). High cholesterol
levels might further add to the risk for cardiovascular
disease (CVD) in cystinosis patients.
Next to the possible deteriorative effect of cystine
accumulation in blood vessels and hypercholesterolemia,
patients with cystinosis can be prone to CVD due to
chronic kidney disease (CKD) (Go et al. 2004). Whether
cysteamine treatment offers a protection against cardio-
vascular damage remains unclear.
Non-invasive measurements of atherosclerosis (NIMA)
have been well established as an indicator for athero-
sclerosis and may be used as a predictor for the
development of CVD. In this study we focussed on two
aspects of atherosclerosis measured by three NIMA in
adult cystinosis patients, in order to investigate the risk
for CVD in this population. These three NIMA include
carotid intima-media thickness (cIMT), which reflects the
atheroma part of the atherosclerotic process, pulse wave
velocity (PWV) and pulse wave analysis (PWA), which
both reflect arterial stiffness.
Patients and methods
All patients≥21 years old who were treated for cystinosis in
the Netherlands were included in this study. A total of 13
patients met these criteria, seven of whom were male.
Mutation analysis of the CTNS gene was performed in 12
patients and confirmed the diagnosis of cystinosis in all of
them, genetic analysis was not performed in one patient.
White blood cell (WBC) cystine levels, measured at least
annually during the last 5 years (range 5-18 years), were
obtained from the patients’ medical records. These values
were used to calculate mean WBC cystine levels. Patients
were considered adequately treated with cysteamine if their
mean WBC cystine level was below 1 nmol cystine/mg
protein. All patients had taken cysteamine in the past, at the
moment of this study it was still taken by 12/13 patients.
Glomerular filtration rate (GFR) was calculated using the
modification of diet in renal disease study equation
(MDRD) (Levey et al. 1999). Hypertension was defined
as a BP of >140/90 mmHg or taking medication for high
BP (K/DOQI 2004).
Measurements of cIMT, PWV and PWA were per-
formed according to a highly standardized protocol and
performed by the same experienced technician in all
patients (Holewijn et al. 2009). Mean cIMT was calculated
from the mean of the following four measured segments:
far wall left, far wall right, near wall left and near wall
right. Subsequently the presence of plaque and its thickness
was measured. Plaque was defined as focal thickening of
the wall of at least 1.5 x mean cIMT.
PWV and PWA were measured with applanation tonom-
etry, using the commercially available SphygmoCor system
version 7.1 (Atcor Medical, Sydney. Australia). PWV was
acquired in 8/13 subjects. Due to logistic reasons, measure-
ments of arterial stiffness could not be performed in all
patients. In two male patients PWA could not be recorded,
since both had a history of multiple shunt surgeries in both
arms. Therefore, PWA measurements were acquired in 6/13
patients. Three parameters of PWA were analyzed; the
augmentation index (AI), the ejection duration and the
Buckberg sub-endocardial viability ratio index (Buckberg
SEVR index). Since the AI strongly depends on heart rate
(Wilkinson et al. 2000), it was corrected for a heart rate of
75 beats per minute.
Results
Clinical and biochemical characteristics of the included
patients are depicted in Table 1. Median age was 28 (range
21-44) years, the female patients were generally older
compared to the male patients. GFR ranged between 4-
95 mL/min/1.73 m². All patients underwent a renal
transplantation in the past, 12 of them still had functioning
renal graft at the time of this study, one male patient was
treated with hemodialysis after graft failure. Median time
after renal transplantation was 14 (range 1-29) years.
Twelve patients were receiving anti-hypertensive drugs.
Eight patients were adequately treated with cysteamine,
proven by mean WBC cystine levels<1 nmol cystine/mg
protein. Five patients (3 male, 2 female) were taking lipid-
lowering medication. Only one female patient, not taking
lipid-lowering medication, had a serum low density
lipoprotein (LDL) cholesterol higher than 3.5 mmol/L. All
patients had a LDL/HDL ratio below five.
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The results of cIMT, PWV, and PWA measurements are
depicted in Table 2 and will be subsequently described in
the sections below.
cIMT measurements
The cIMT measurements were performed in all 13
patients. Median cIMT was 0.64 (range 0.54-0.82) mm.
In none of the patients plaques were detected at the
carotid arteries. When compared to a healthy population
of the same age (normal range±2 SD: men 0.39-0.79 mm,
women 0.41-0.73 mm, n=2265) (Juonala et al. 2008),
mean cIMT values were more than 2 SD above the
expected mean in only 1 female with CKD stage 3 (patient
3), who had a functional renal graft since 14 years and was
adequately treated with cysteamine. However, when cor-
rected for CKD stage (Hogg et al. 2003), cIMT levels were
within or even below the normal range in all patients
(Fig. 1a) (Yilmaz et al. 2010).
PWV measurements
PWV measurements were performed in eight patients, five of
whom were male. Men had higher PWV levels compared to
women, with a median value of 7.2(range 5.6-9.4) m/s and 6.1
(range 4.8-7.5) m/s, respectively. When compared to healthy
subjects of the same age, one male patient (patient 8) had a
PWV value of more than 2 SD above the expected mean
(normal range±2 SD: 20-29 years 4.7-7.6 m/s, 30-39 years
3.8-9.2 m/s, 40-49 years 4.6-9.8 m/s, n=1455) (Mattace-Raso
et al. 2010). The patient with a high PWV value had CKD
stage 2 and had a functional renal graft since 15 years, he was
adequately treated with cysteamine. When corrected for CKD
stage (Hogg et al. 2003), all PWV levels were within a range
of 2 SD of the expected mean (Fig. 1b) (Wang et al. 2005).
PWA measurements
PWA measurements were performed in six patients (three of
whom were male). Since there are no reference values
available from literature for CKD patients with an age
comparable to our population, the measured values were
compared to the normal ranges provided by the manufacturer
of the program. The median AI was 25% (range 2%-41%).
Normal values depend on age, they should be below 15% at
30yearsandbelow22%at40years.Threepatientshadvalues
above the normal range (2 female, 1 male). The ejection
duration remained within the normal range of 250-350 ms in
all patients. The median Buckberg SEVR index was 176%
(range 164%-204%). All patients had a Buckberg SEVR
index above 150%, indicating that myocardial perfusion was
not reduced.
Table 2 Results of non-invasive measurements of atherosclerosis
Pt Sex Age
(years)
Blood pressure
(mmHg)
Mean cIMT
(mm)
a
PWV
(m/s)
b
AI
(%)
c
ED
(ms)
d
Buckberg SEVR index
(%)
e
1 F 31 132/82 0.65 7.5 41 277 173
2 M 33 116/70 0.64 5.6 14 349 164
3 M 23 102/68 0.66 6.0 30 295 188
4 F 36 120/74 0.81 6.1 40 343 171
5
* F 21 119/82 0.62 4.8 2 313 179
6 M 44 116/84 0.63 9.4 20 337 204
7 M 22 112/72 0.71 7.2
8 M 29 128/84 0.60 8.4
9 M 21 120/75 0.60
10 F 41 135/90 0.68
11
§ F 27 148/100 0.60
12
§ F 28 152/92 0.64
13
* M 22 140/68 0.54
*, § Siblings
a cIMT: carotid intima-media thickness, normal values depend on age and renal function (see text)
b PWV: pulse wave velocity, normal values depend on age and renal function (see text)
c AI: augmentation index after correction for a heart rate of 75 beats/minute, normal values<15% at 30 years,<22% at 40 years
d ED: Ejection duration, normal 250-350 ms
e SEVR: sub-endocardial viability ratio, normal>150%
814 J Inherit Metab Dis (2011) 34:811–818Influence of therapy on NIMA
To evaluate a possible effect of both adequate treatment of
cystinosis (defined as mean WBC cystine levels<1 nmol
cystine/mg protein) and the administration of lipid-lowering
medication on NIMA, we displayed our results in function
of the patients’ treatments. Figure 2a-c show NIMA values
in patients with mean WBC cystine levels either below or
above 1 nmol cystine/mg protein, Fig. 2e-f shows NIMA
values in patients either on or off lipid-lowering medica-
tion. In our study population neither mean WBC cystine
levels, nor lipid-lowering medication had an effect on cIMT
levels (Fig. 2a and d) or PWV values (Fig. 2b and e). PWA
measurements were conducted in only 1 patient with high
WBC cystine levels (patient 1), she showed a clearly
increased AI (Fig. 2c). None of the three patients with an
increased AI was taking lipid-lowering medication
(Fig. 2f).
Discussion
Since increasing numbers of individuals with cystinosis are
receiving renal transplants and live into adulthood, more
long-term complications of the disease are being recog-
nized. Most likely, the full spectrum of extra-renal
Fig. 1 cIMT and PWV values classified by CKD stage. a: Mean total
cIMT values classified by CKD stage. b: PWV classified by CKD
stage. The bars indicate the normal range for that particular CKD
stage. Both cIMT and PWV values are within or below the normal
range when corrected for CKD stage
Fig. 2 Effect of cysteamine and lipid-lowering medication on NIMA.
Effectofadequatecysteaminetreatment,indicatedbymeanWBCcystine
levels<1 nmol cystine/mg protein, on cIMT (a), PWV (b) and AI (c).
There is no clear effect of WBC cystine levels on cIMT. PWVand PWA
measurements were conducted in only one patient with high WBC
cystine levels, she showed a clearly increased AI. Effect of lipid-
lowering medication on cIMT (d), PWV (e)a n dA I( f). There is no
clear difference between cIMT and PWV values of patients who take
lipid-lowering medication, compared to those who do not. The three
patients with an increased AI did not take any lipid-lowering medication
J Inherit Metab Dis (2011) 34:811–818 815involvement in cystinosis has not yet been elucidated, since
many of the long-term complications were recognized only
after renal transplantation allowing patients to survive past
adolescence. Ueda et al. added arteriopathy to the list of
long-term complications of cystinosis. Their conclusion
was based on the fact that they found increased vascular
calcifications on routine chest and head computed tomog-
raphy (CT) scans (Ueda et al. 2006).
To our knowledge, we for the first time investigated the
risk for CVD by three NIMA in cystinosis patients,
including cIMT, PWV and PWA, allowing a thorough risk
evaluation for CVD in this population. The most
important finding of this study is that we found normal
NIMA in adult cystinosis patients with extended co-
morbidity such as diabetes, hypertension and renal failure,
when correction for CKD stage was made. The main
limitation of this study is the small study population, since
cystinosis is a very rare disease. Secondly, we did not
have a control group of patients with CKD without
cystinosis, but we used the studies of Yilmaz et al. and
Wang et al. to compare our results (Yilmaz et al. 2010,
Wang et al. 2005).
Non-invasive measures of atherosclerosis
An increased cIMT may reflect hypertrophy of the intimal
and/or medial layer of the carotid arteries, which can be
caused by changes in flow, wall tension or lumen diameter
(Stein et al. 2008). Since the outcome of cIMT measure-
ments is influenced by renal function, we compared our
data to those measured in patients with different stages of
CKD (Yilmaz et al. 2010) and found no increase of cIMT
values in our study population when compared with
patients with the same CKD stage without cystinosis. On
the contrary, in cystinosis patients with CKD stage five we
found cIMT values that were lower than one would expect
according to their renal function (Fig. 1). However, when
compared to a healthy population of the same age, one
patient had a mean cIMT level more than 2 SD above the
expected mean which could not be explained by fluid
overload.
PWV reflects the degree of arterial stiffness. Overall,
men had higher PWV values than women contrasting other
studied demonstrating no differences in PWV related to
gender (Smulyan et al. 2001). There was no clear difference
between cIMT values, nor was there a difference between
blood pressure values between men and women (Table 2).
Since our study population was rather small, no conclusion
can be drawn from this observation.
In 2005, Wang et al. published PWV values for a
large group of CKD patients. Their study population was
older than ours, but they used the same equipment to
perform their measurements as we did (Wang et al.
2005). Mourad et al. also investigated PWV values in
younger CKD patients, however, they used the Complior
device to perform their measurements (Mourad et al.
2001). This makes their results more difficult to compare
with ours, since both techniques are not interchangeable
(Jatoi et al. 2009). Therefore, we compared our values to
those published by Wang et al. All PWV values measured
in our patients were within 2 SD of the expected mean for
the corresponding CKD stage. However, PWV values
were more than 2 SD above the expected mean in one
patient when compared to healthy subjects of the same
age.
The correlation between PWA and cIMT in CKD
patients has been well documented (DeLoach et al.
2009). PWA measures can be divided into three sub-
groups: timing parameters (e.g. heart rate, ejection
duration), pressure parameters (e.g. peripheral diastolic
and systolic blood pressure, central diastolic and systolic
blood pressure) and central aortic indeces (e.g. AI,
Buckberg SEVR index). Together they estimate the
reflection of the arterial wave in the central circulation.
In this study, we foccussed on three measures of PWA,
including AI, ejection duration and the Buckberg SEVR
index. In our study population we found an increased AI
in 3/6 patients, two of which were female. In adults the AI
is generally higher in females than in males (Yasmin and
Brown 1999). We found no reflection on myocardial
perfusion as measured by the Buckberg SEVR index,
which was within the normal range in all patients. Overall,
there were no clear abnormalities of PWA values in our
study population.
The fact that we found low values for cIMT in some
patients when corrected for CKD stage, remains interesting.
This could be partially explained by the differences in age
between our study population and the study population
used to generate the reference values. Furthermore, differ-
ent kinds of medication were used, which could have
interfered with the outcomes of the measurements. Most of
our patients were treated with antihypertensive drugs and/or
lipid-lowering medication starting from an early age, both
of which are known to positively influence NIMA (Simon
et al. 2002). It should be noted that when compared to
healthy subjects of the same age, some patients showed
rather high cIMT and PWV levels, reflecting increased
stages of the atherosclerotic process, suggesting an in-
creased risk for CVD.
Influence of therapy on NIMA
It is currently unknown whether cysteamine, which is
used to treat cystinosis, may influence NIMA. In this
study, we found no differences between cIMT values in
patients who were adequately treated with cysteamine
816 J Inherit Metab Dis (2011) 34:811–818(WBC cystine levels<1 nmol/mg protein) and those who
were not (Fig. 2a), however, the group of patients who
were less well treated was small (n=5). The only patient
who was not treated with cysteamine at the moment of this
study, did receive cysteamine treatment in the past.
Measurements of PWVand PWA conducted in this patient
demonstrated normal PWV values (Fig. 2b), but her AI
was increased (Fig. 2c). However, the fact that this
observation was made in only one patient makes it
impossible to draw conclusions from these results. On
the other hand, the fact that most patients had lower NIMA
values than one would expect according to CKD stage and
the fact that all patients but one were taking cysteamine,
might indicate a protective effect of cysteamine. NIMA
measurements in a less adequately treated cystinosis
population are required to test this hypothesis. It should
be stressed out that Ueda et al. found a strong correlation
between the number of years without adequate cysteamine
therapy and the appearance of vascular calcifications on
CT (Ueda et al. 2006). We were not able to determine
years on and off cysteamine therapy, since most patients
were treated in more than one hospital and several patients
had been on and off therapy over the last years. However,
all WBC cystine measurements were conducted in our
laboratory, independent of the hospital of clinical follow-
up. Therefore, we chose to use mean WBC levels as a
measure of cysteamine treatment.
In contrast to previous reports (Nesterova and Gahl
2008, Murphy and Papathakis 1993) we found no large
abnormalities in lipid status in our study population
(Table 1), which might be due to treatment with lipid-
lowering medicaton. However, we did not observe a
difference in cIMT and PWV values between patients
w h ow e r et a k i n gl i p i d - l o w e r i n gm e d i c a t i o na n dt h o s ew h o
did not (Fig. 2d and e). The three patients with an
increased AI, however, were all not taking lipid-lowering
medication (Fig. 2f). This increased AI did not have a
reflection on myocardial perfusion, since all patiens had a
normal Buckberg SEVR index. These findings are in line
with the study of Ueda et al., in which no difference in
cholesterol parameters was found between cystinosis
patients with and without vascular calcifications on CT
(Ueda et al. 2006).
Conclusion
In conclusion, we demonstrate no increased risk for CVD in
young adult cystinosis patients treated with cysteamine.
Attention should be paid to long-term follow-up of these
patients, including changes of NIMA over time, as it can
provide more insight in the possible development of
vascular damage in this population.
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